Hidradentitis Suppurativa

Hidradenitis Suppurativa: Current and Future Treatments
November 11, 2022

Hidradenitis suppurativa is a chronic inflammatory skin condition that presents with painful, deep, and inflamed lesions found in flexural, apocrine gland-bearing sites.

Exploring What’s Possible for HS Treatment
October 22, 2022

At the 2022 Fall Clinical Dermatology Conference, Joslyn R. Sciacca Kirby, MD, MS, MEd, and Raj Chovatiya, MD, PhD, discussed how there is a large unmet need for hidradenitis suppurativa treatment and what future treatment could look like.

Positive Results from 2 Novartis Trials for HS Treatment
September 13, 2022

SUNSHINE and SUNRISE trials showed superior efficacy over the placebo.

Evidence of Cumulative Life Course Impairment in Hidradenitis Suppurativa
September 09, 2022

Study data was presented at EADV 2022 regarding socioeconomic status related to HS.

Imsidolimab Development for HS Discontinued
September 02, 2022

AnaptysBio will refocus R&D efforts on its immune cell modulator pipeline.

Effectively Treating Hidradenitis Suppurativa
June 25, 2022

Theodore Rosen, MD, details his top tips for treating hidradenitis suppurativa.

Hidradenitis Suppurativa in Pregnancy
June 08, 2022

This painful skin disease may lower the odds of live birth and trigger comorbidities.

Updates in HS and PRP
March 26, 2022

In this video interview, we sit down with both Jennifer Lin Hsiao, MD, FAAD, and Scott Worswick, MD, FAAD, to talk in detail about their presentation, "Hidradenitis Suppurativa and Pityriasis Rubra Pilaris: Updates on Treatments for Two Conditions that are Difficult to Manage."

Almirall Collaborates with University of Michigan to Understand HS
March 15, 2022

Almirall announced today that it will work with the University of Michigan to better understand disease drivers in hidradenitis suppurativa.